Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic tetrapeptide
Testagen is a marketed name for KEDG, a short peptide studied in pituitary, pancreatic, and cell-aging models.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Testagen is a marketed name for KEDG, a short peptide studied in pituitary, pancreatic, and cell-aging models. It is not an approved endocrine treatment.
Researchers use fluorescent labels and animal models to explore whether KEDG enters cells or changes pituitary-related markers. These experiments test basic biology before clinical outcomes.
Laboratory work found that labeled KEDG entered cultured cells and localized within cellular compartments. Animal and cell studies reported changes in pituitary-related markers. Relay found no controlled administered-human study measuring hormone outcomes, symptoms, fertility, or safety.
Human absorption, endocrine target engagement, clinical benefit, reproductive effects, off-target growth signaling, interactions, product identity, and long-term safety remain unknown. Cell entry and animal marker changes do not establish endocrine improvement in people.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published research exposed cultured cells to fluorescently labeled KEDG and tracked whether the peptide entered and localized within the cells.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Laboratory and animal evidence; no controlled administered-human outcome study located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human pharmacokinetics, endocrine outcomes, reproductive effects, off-target growth signaling, and longer-term safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Participants were not treated, and cell entry is not a clinical outcome. The study cannot establish human absorption, pituitary benefit, endocrine effects, reproductive safety, or long-term risk. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Human-derived cells have been studied in vitro; no controlled human administration trial was located.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Human pharmacokinetics, endocrine outcomes, reproductive effects, off-target growth signaling, and longer-term safety.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
KEDG can enter cultured cells and has been associated with gene-expression changes in experimental systems. These findings do not establish endocrine restoration in humans.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Cell-culture uptake study
Population not stated.
Fluorescently labeled KEDG entered cultured cells and localized to cellular compartments.
Study administration: Not stated in the current record.
Limitations: Cell penetration does not establish a therapeutic outcome.
Animal and laboratory study
Rodents and cultured cells
Endpoints were not fully described in the current record.
Animal and cell studies reported changes in pituitary-related markers.
Study administration: Not stated in the current record.
Limitations: Preclinical marker changes do not establish human endocrine benefit.
Safety snapshot
Current evidence cannot yet resolve: Human pharmacokinetics, endocrine outcomes, reproductive effects, off-target growth signaling, and longer-term safety.
No direct evidenceAn absence of adequate evidence is not evidence of benefit, harm, or equivalence.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryPreclinical; no FDA-approved Testagen/KEDG product. Human pharmacokinetics, endocrine outcomes, reproductive effects, off-target growth signaling, and longer-term safety.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 22117547
PMID 20731122